-- Genmab (GMAB) 週一表示，一項名為 Rainfol-01 的 1/2 期臨床試驗數據顯示，rinatabart sesutecan 聯合貝伐單抗治療晚期卵巢癌患者耐受性良好，且未發現新的安全性信號。 這項納入 40 名患者的試驗中，最常見的治療期間出現的不良事件 (TAE) 包括噁心、疲倦、貧血和嗜中性白血球減少症。該公司表示，6 名患者發生了嚴重 TAE，11 名患者因 TAE 導致 rinatabart sesutecan 劑量減少，2 名患者因 TAE 導致貝伐單抗停藥。
Related Articles
Asia
Origin Energy Reports Lower March Quarter Production
Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.
$ASX:ORG
Asia
New Hope Says JPMorgan Chase Ceases to be a Substantial Shareholder
New Hope (ASX:NHC) received notice that JPMorgan Chase and its affiliates are no longer substantial holders of the company from April 22, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates became a substantial holder of the company on April 15, with a total voting power of 5.88%, an earlier filing showed.
$ASX:NHC
Asia
Zip Says JPMorgan Chase Increases Stake
Zip (ASX:ZIP) received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 7.42% from 6.27%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now own 93.2 million shares in the company, the filing said.
$ASX:ZIP